drugset / Trial / NCT01213368

Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation

NCT01213368

Phase 2 Completed 181 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary Objective: \- To assess the efficacy of dronedarone versus placebo for the control of ventricular rate in patients with permanent Atrial Fibrillation (AF). Secondary Objective: * To assess the safety and tolerability of dronedarone after repeated oral doses of 300 mg, 400 mg, or 600 mg twice daily in the selected population. * To document SR33589 and SR35021 trough plasma levels at steady state.

Timeline

Start
2010-09
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronedarone Small molecule 300 mg Oral
Subject Dronedarone Small molecule 400 mg Oral
Subject Dronedarone Small molecule 600 mg Oral

Indications